image description

News. Other News

Juventas to Launch Phase 3 Study Next Year

Juventas to Launch Phase 3 Study Next Year
cleveland.com, May 30, 2014

Clinic Focuses on Commercializing Medical Products

Clinic Focuses on Commercializing Medical Products
Plastics News, May 28, 2014

Juventas Therapeutics new therapeutic delivery approach trial initiated, featured in press

Juventas Therapeutics new therapeutic delivery approach trial initiated, featured in press
November 27, 2013

Cleveland Clinic-led group gets $10 million to become one of three NIH Centers for Accelerated Innovations

Cleveland Clinic-led group gets $10 million to become one of three NIH Centers for Accelerated Innovations
Angela Townsend, The Plain Dealer, September 26, 2013
Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial. The 90-patient, placebo-controlled, randomized double-blinded Phase II study is evaluating the safety and efficacy for JVS-100 in patients with late stage heart failure. Dr. Amit Patel, the Director of Clinical Regenerative Medicine at University of Utah Medical Center, treated the patient.

Juventas Therapeutics doses first patient in Phase II STOP-HF trial

Juventas Therapeutics
PRNewswire-USNewswire, August 20, 2012
Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial. The 90-patient, placebo-controlled, randomized double-blinded Phase II study is evaluating the safety and efficacy for JVS-100 in patients with late stage heart failure. Dr. Amit Patel, the Director of Clinical Regenerative Medicine at University of Utah Medical Center, treated the patient.

Cleveland Clinic Spin-Off Company, Cleveland Heart Inc., Receives $30 Million Investment for Development of Artificial Heart

Cleveland Heart Inc.
Innovation, July 16, 2012
Cleveland Clinic Spin-Off Company, Cleveland Heart Inc., Receives $30 Million Investment for Development of Artificial Heart

Juventas Therapeutics Raises $22.2 Million Series B Financing

Juventas Therapeutics
PRNewswire, July 16, 2012
Juventas Therapeutics, a clinical-stage regenerative medicine company, announced today that it has closed a $22.2 million Series B financing that was co-led by Triathlon Medical Venture Partners and New Science Ventures